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ABSTRACT
Introduction: A 12-week prospective study was
previously performed to assess the effect of
add-on therapy with sitagliptin, a dipeptidyl
peptidase-4 (DPP-4) inhibitor, in patients with
type 2 diabetes mellitus (T2DM) receiving
insulin treatment. Patients were followed until
week 48 to investigate the medium-term
efficacy and safety of the add-on therapy with
sitagliptin.
Methods: In the 70 patients with T2DM,
glycemic control, insulin dosage, concomitant
medications, body weight, laboratory
parameters, and adverse events were evaluated
for 48 weeks.
Results: Hemoglobin A1c (HbA1c) improved
significantly from 8.03% at week 0 (at
initiation of the add-on therapy) to 7.45% at
week 48 (P\0.01). Body weight remained
nearly the same. The daily insulin dose was
significantly reduced by 2.5 U, from 25.8 to
23.3 U/day (P\0.001). Stratified analysis of the
improvement of HbA1c based on age, duration
of diabetes, body mass index, insulin regimen,
and oral antidiabetic drugs did not identify any
significant differences in relation to these
parameters. During the 48-week follow-up
period, there were no problematic adverse
events, such as severe hypoglycemia, and the
add-on therapy with sitagliptin showed good
tolerability.
Conclusions: In Japanese patients with T2DM
receiving insulin treatment, add-on therapy
with sitagliptin was not associated with weight
gain and allowed for the reduction of the
insulin dosage. Consistent efficacy was noted
for 48 weeks without an increasing
hypoglycemic effect, and the add-on therapy
with sitagliptin was effective irrespective of the
insulin regimen.
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INTRODUCTION
The usefulness of dipeptidyl peptidase-4 (DPP-4)
inhibitors for the treatment of type 2 diabetes
mellitus (T2DM) is widely known in Japan.
While combination therapy with insulin
injections and a DPP-4 inhibitor has been
investigated in clinical studies [1, 2], to date
only a few reports have discussed the usefulness
and safety over a long treatment period [3].
Insulin regimens used in the management of
T2DM include long-acting insulin given once
daily, premixed insulin given twice or thrice
daily, and multiple daily insulin injections
(basal-bolus therapy), as well as a variety of
regimens combining insulin and oral
antidiabetic drugs. In insulin-treated patients
with T2DM, the duration of diabetes is longer
and hypo-secretion of endogenous insulin is
common, but their clinical characteristics are
not homogeneous. Therefore, the authors
considered that prospective clinical studies
should be conducted to identify the patient
populations which would benefit from
concomitant treatment with insulin and a
DPP-4 inhibitor. The authors have previously
reported the short-term results of add-on
therapy with sitagliptin in patients with T2DM
receiving insulin, who were assessed
prospectively for 12 weeks [4]. In this study,
the medium-term results of the add-on therapy
with sitagliptin up to 48 weeks was evaluated by
follow-up of the same patient population to
monitor glycemic control, insulin dosage,
concomitant drugs, body weight, and adverse
events. The objective of this study was to
investigate whether the combination therapy
maintains good glycemic control for 48 weeks
with acceptable safety.
METHODS
The patients with T2DM recruited for this
study were treated at Hyogo College of
Medicine and Ikeda Hospital from September
2011 to June 2013, and fulfilled the following
eligibility criteria. Inclusion criteria for this
study were as follows: (1) age C20 years, (2)
T2DM treated with insulin therapy [basal
insulin with oral antidiabetic drugs (basal
insulin therapy), twice daily injection of
premixed insulin, or multiple daily insulin
injections] for at least 6 months, and (3)
hemoglobin A1c (HbA1c) C6.9% [National
Glycohemoglobin Standardization Program
(NGSP) value]. The exclusion criteria were the
following: (1) type 1 diabetes, (2) severe
complications of diabetes, (3) severe
hypoglycemia or recurrent asymptomatic
hypoglycemia, (4) severe infection, (5)
patients scheduled for surgery or those with
severe trauma, (6) pregnant or nursing women
and women who could possibly become
pregnant, and (7) other patients whom the
investigator judged to be inappropriate for the
study.
The study protocol was reviewed and
approved by the Ethics Committee of Hyogo
College of Medicine. All procedures followed
were in accordance with the ethical standards of
the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients before inclusion in the study.
All subjects were given an explanation of the
details of the study and voluntarily gave written
informed consent to participation. After
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completion of the 12-week study, informed
consent was again obtained to continue
administration of sitagliptin.
Patients who fulfilled the above eligibility
criteria continued to receive the add-on therapy
with sitagliptin 50 mg given once daily after
breakfast for 48 weeks. Throughout the study
period, in patient instruction, emphasis was
placed on avoiding hypoglycemic episodes
based on data obtained by self-monitoring of
blood glucose.
The primary endpoint was changes in HbA1c
up to 48 weeks. HbA1c, blood glucose, and body
weight were measured every 4 weeks. In
addition, serum C-peptide reactivity index
(CPI) was measured at weeks 0, 12, 24, and 48.
Adverse events were monitored throughout the
study period.
Statistical Analysis
Changes in HbA1c during sitagliptin treatment
were analyzed by one-way analysis of variance.
Changes in each parameter at week 48
compared to those measured at the initiation
of sitagliptin treatment (baseline) were
evaluated by paired t test or Mann–Whitney
U test. Comparisons between groups were done
with Mann–Whitney U test, Kruskal–Wallis test,
or Steel–Dwass test as appropriate. For stratified
analysis based on the insulin regimen,
demographic data were compared by Bartlett’s
test, Kruskal–Wallis test, or Chi-square test. All
analyses were carried out using SAS software
version 8.02 (SAS Institute Inc., Cary, NC, USA)
and statistical significance was accepted at
P\0.05. Data are expressed as the
mean ± standard deviation. NGSP equivalent
values were calculated for HbA1c (%) values
determined according to the Japan Diabetes
Society (JDS) method (HbA1c
[NGSP] = 1.02 9 HbA1c [JDS] ? 0.25%), based
on the reported relationship between HbA1c
(NGSP) values and HbA1c (JDS; %) values
measured by the standard Japanese method.
RESULTS
After exclusion of 1 patient who discontinued
treatment after completing week 12, 70 patients
were included in this study. Another patient
was transferred to a different hospital during




Table 1 shows the baseline characteristic of 70
patients enroled in the study. The mean daily
insulin dose was 25.7 ± 14.8 U/day. While most
patients were receiving concomitant oral
antidiabetic drugs such as sulfonylureas
(60.0%), a-glucosidase inhibitors (38.6%), and
metformin (32.9%), 12 patients (17.1%) were
on insulin monotherapy.
Changes in HbA1c
Changes in HbA1c were the primary endpoint
of this study. HbA1c decreased significantly
from 8.03 ± 1.07% at week 0 (at the time of
initiation of the add-on therapy) to
7.51 ± 0.91% after 12 weeks (P\0.01),
7.59 ± 1.09% after 24 weeks (P\0.05), and
7.45 ± 1.03% after 48 weeks (P\0.01; Fig. 1).
Changes in Other Parameters
Table 2 shows changes in other parameters after
48 weeks. Body weight remained nearly the
same at 66.7 kg throughout the 48 weeks,
showing no significant change. There was a
significant improvement in CPI after 48 weeks.
The insulin dosage also significantly decreased.
After 48 weeks, insulin therapy was
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discontinued in 2 patients (2.9%) and the
insulin dose was reduced in 35 patients
(50.0%), with the mean reduction being
6.6 ± 5.3 U/day. The insulin dose was
increased in 10 patients (14.3%), with a mean
increase of 4.5 ± 2.3 U/day, while there was no
change in insulin dosage in the remaining
patients.
With regard to oral antidiabetic drugs, 42
patients were concomitantly using
sulfonylureas. These drugs were discontinued
in two patients (4.8%), the daily dose was
decreased in 10 patients (23.8%) and increased
in three patients (7.1%), and the sulfonylurea
dosage was not changed in other patients.
Severe Hypoglycemia and Adverse Events
None of the patients experienced severe
hypoglycemia that required assistance by a
third party or treatment including intravenous
infusion. In addition, none of the patients
discontinued the administration of sitagliptin
due to an adverse event.
Stratified Analysis by Patient
Characteristics
Evaluation of Patients Responding
to the Add-On Therapy
To identify patients for whom the add-on
therapy with sitagliptin showed high efficacy,
correlations between the hypoglycemic effect
(change in HbA1c from week 0 to week 48) and
Table 1 Baseline demographic and clinical characteristics
(n = 70)
Characteristics Value




Body weight (kg) 66.7 ± 11.9
Body mass index (kg/m2) 25.8 ± 3.8
Duration of diabetes (years) 18.2 ± 10.4
HbA1c (NGSP), % 8.03 ± 1.07
CPI 1.27 ± 0.81
Duration of sulfonylurea therapy (years) 9.3 ± 7.1
Insulin dose (U/day) 25.7 ± 14.8
Insulin dose per body weight (U/day/kg) 0.39 ± 0.26
Insulin therapy, n (%)
Twice daily injections 45 (63.3)
Multiple daily injections 14 (20.0)
Basal therapy 11 (15.7)
Oral antidiabetic drugs, n (%)
None 12 (17.1)
Sulfonylureas 42 (60.0)




Data are shown as the mean ± standard deviation unless
otherwise stated
CPI C-peptide reactivity index, HbA1c hemoglobin A1c,



















Fig. 1 Changes in HbA1c from week 0 to week 48.
*P\0.05, **P\0.01 (vs. week 0) by Dunnett’s test.
HbA1c hemoglobin A1c
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various baseline characteristics were evaluated;
a high baseline HbA1c was identified as a factor
that was significantly associated with the
decrease in HbA1c (r = -0.29249, P = 0.00180;
Table 3).
Influence of Specific Factors
The influences of specific baseline factors (age,
BMI, CPI, and oral hypoglycemic agents) on
changes in HbA1c after 48 weeks were
investigated by stratifying patients as shown in
Fig. 2 For all factors, the stratified groups
showed a significant decrease in HbA1c, but
no significant difference was found between the
groups (Fig. 2).
Stratified Analysis by Insulin Regimen
Profile of the Three Insulin Regimen Groups
The insulin regimen was twice daily injection of
premixed insulin in 45 patients (64.3%, twice
daily group), multiple daily injections of insulin
in 14 patients (20.0%, multiple injections
group), and basal insulin therapy in 11
patients (15.7%, basal insulin group). Table 4
shows the baseline characteristics of each
group.
Changes in HbA1c by Insulin Regimens
HbA1c decreased significantly after 48 weeks in
all three groups; there was no significant
Table 2 Changes in parameters at week 48 from baseline (n = 69)
Parameters Baseline (Week 0) Week 48 Change from baseline P value (vs. baseline)
Body weight (kg) 66.7 ± 11.9 66.7 ± 12.5 -0.03 ± 2.25 0.9306a
CPI 1.27 ± 0.74 1.54 ± 1.38 0.32 ± 1.34 0.0050b
Insulin dose (U/day) 25.8 ± 14.8 23.3 ± 15.8 -2.5 ± 5.3 \0.001a
Data are shown as the mean ± standard deviation
CPI C-peptide reactivity index
a Paired t test
b Mann–Whitney U test
Table 3 Multiple linear regression analysis of changes in HbA1c from baseline to week 48 in all patients (age, duration of
diabetes, BMI, HbA1c, CPI, insulin dose, and duration of sulfonamide therapy; n = 69)
Parameters Regression coefﬁcient Standard error P value
Age -0.00635 0.00905 0.48551
Duration of diabetes 0.00498 0.01087 0.64869
BMI -0.01441 0.02678 0.59249
HbA1c -0.29249 0.08960 0.00180
CPI 0.04096 0.10724 0.70386
Insulin dose 0.00751 0.00699 0.28692
Duration of sulfonylurea therapy -0.01030 0.01502 0.49537
BMI body mass index, CPI C-peptide reactivity index, HbA1c hemoglobin A1c
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difference between the three insulin regimens
(Fig. 3).
Changes in Other Parameters by Insulin
Regimens
Table 5 shows changes in other parameters by
three insulin regimens. For all parameters (body
weight, CPI, and insulin dosage), there was no
significant difference between the three insulin
regimens in terms of changes in parameters
from baseline to week 48.
DISCUSSION
In this study that investigated the effects of the
combination therapy of sitagliptin and insulin
in 70 Japanese patients with T2DM, there were
four main findings: (1) The insulin dosage was
reduced significantly after 48 weeks without
weight gain; (2) HbA1c was decreased by 0.58%
after 48 weeks compared with the baseline
value; (3) There were no problematic adverse
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Fig. 2 Changes in HbA1c from week 0 to week 48 in each
subgroup stratiﬁed by a age, b BMI, c CPI, and d OHAs.
a-GI alpha glucosidase inhibitor, BG biguanide, BMI body
mass index, CPI C-peptide reactivity index, HbA1c
hemoglobin A1c, OHA oral hypoglycemic agent, NS not
signiﬁcant, SD standard deviation, SU sulfonylurea
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CPI was significantly higher after 48 weeks,
indicating that endogenous insulin secretion
was improved. These results suggested that the
combination of insulin and sitagliptin is
effective for the treatment of T2DM over the
medium term (48 weeks) and shows good
tolerability.
When the target HbA1c level cannot be
achieved by insulin therapy for a certain
period, the general approach is to consider
changing the insulin preparation, dosage, or
regimen. While a higher insulin dosage and
changing the regimen may temporarily improve
glycemic control, it is likely to cause an
increased risk of hypoglycemia and weight
gain. This can lead to a vicious cycle of
deteriorating glycemic control and further
insulin dose escalation, as demonstrated in
some large-scale clinical studies including the
United Kingdom Prospective Diabetes Study








Age (years) 65.1 ± 10.0 62.9 ± 8.8 61.3 ± 13.8 0.2841a
Sex, n (%)
Male 20 (44.4) 10 (71.4) 8 (72.7) 0.0854c
Female 25 (55.6) 4 (28.6) 3 (27.3)
Body weight (kg) 66.3 ± 13.0 70.6 ± 12.3 62.3 ± 6.0 0.0376a
Body mass index (kg/m2) 25.4 ± 3.5 26.5 ± 4.6 23.6 ± 3.2 0.4629a
Duration of diabetes (years) 18.3 ± 10.9 17.4 ± 10.7 18.2 ± 8.7 0.6890a
HbA1c (NGSP), % 8.05 ± 1.19 7.98 ± 0.73 8.01 ± 1.00 0.3148a
CPI 1.32 ± 0.88 1.22 ± 0.82 1.11 ± 0.51 0.4261b
Duration of sulfonylurea therapy (years) 9.3 ± 7.8 6.5 ± 6.9 12.5 ± 4.2 0.0973a
Insulin dose (U/day) 26.4 ± 13.0 32.3 ± 19.7 15.4 ± 7.0 0.0026a
Insulin dose per body weight (U/day/kg) 0.4 ± 0.2 0.4 ± 0.2 0.2 ± 0.1 0.0058a
Oral antidiabetic agents, n (%)
None 8 (17.7) 3 (21.4) 0 0.1939c
Sulfonylureas 28 (62.2) 4 (28.6) 10 (90.9) 0.0035c
a-Glucosidase inhibitors 18 (40.0) 3 (21.4) 7 (63.6) 0.0790c
Metformin 15 (33.3) 6 (42.9) 3 (27.3) 0.7900c
Glinides 5 (11.1) 0 (0.0) 0 (0.0) 0.2114c
Thiazolidinediones 0 (0.0) 0 (0.0) 1 (9.1) 0.0629c
Data are shown as the mean ± standard deviation unless otherwise stated
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(UKPDS) [5]. To address these issues,
concomitant treatment with insulin and oral
antidiabetic drugs has been employed.
Consequently, improvement of glycemic
control, a decrease in the risk of
hypoglycemia, and a reduction of the insulin
dosage as a result of this concomitant treatment
have been confirmed by clinical research [6].
The efficacy and safety of sitagliptin were
demonstrated by a placebo-controlled
double-blind study performed in Japan [2]. In
the authors’ previous 12-week prospective
clinical study to determine the effects of


































Fig. 3 Changes in HbA1c after 48 weeks of add-on
sitagliptin therapy in relation to the baseline insulin
regimen. HbA1c hemoglobin A1c, NS not signiﬁcant, SD
standard deviation
Table 5 Changes in parameters by insulin regimens at week 48 from baseline (n = 69)
Parameters Baseline
(Week 0)






Twice daily group (n = 44) 66.9 ± 12.6 66.6 ± 13.4 -0.03 ± 2.70 0.9531a NSc
NSdMultiple group (n = 14) 71.7 ± 10.9 70.6 ± 12.5 -0.03 ± 2.2 0.9621a
Basal group (n = 11) 62.3 ± 6.0 61.4 ± 5.8 -0.23 ± 0.83 0.7039a
CPI
Twice daily group (n = 44) 1.30 ± 0.889 1.46 ± 0.81 0.16 ± 0.61 0.0013b NSc
NSdMultiple group (n = 14) 1.25 ± 0.79 1.40 ± 0.91 0.36 ± 0.73 0.5715b
Basal group (n = 11) 1.11 ± 0.51 1.97 ± 2.86 0.95 ± 2.96 0.9439b
Insulin dose (U/day)
Twice daily group (n = 44) 26.4 ± 13.3 24.1 ± 13.9 -2.4 ± 5.0 0.0036a NSc
NSdMultiple group (n = 14) 32.4 ± 19.7 27.9 ± 23.3 -4.5 ± 7.5 0.0392a
Basal group (n = 11) 15.0 ± 6.5 14.1 ± 6.0 -0.91 ± 1.38 0.0531a
Data are shown as the mean ± standard deviation
CPI C-peptide reactivity index, NS not signiﬁcant
a Paired t test
b Mann–Whitney U test
c Kruskal–Wallis test
d Steel–Dwass test
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various insulin regimens, it was found that good
glycemic control was achieved without
problematic adverse events, confirming the
tolerability and usefulness of add-on therapy
with sitagliptin [4]. The authors considered that
safety and efficacy should be investigated for a
longer period than 12 weeks, since T2DM
requires a long-term treatment. Therefore, the
patients from our previous study were followed
up to week 48 in this study. The authors found
that HbA1c was still significantly lower than the
baseline level after 48 weeks, while there was no
change in body weight compared to the
baseline level. Also, no serious adverse event
was observed during the 48-week observation
period; thus, the results of the present study
confirmed those of the previous short-term
study.
Some previous studies have evaluated the
effects of add-on therapy of sitagliptin in
insulin-treated patients. In a randomized
controlled study that compared an ongoing
insulin therapy group (twice daily or more) with
a sitagliptin add-on group (50 mg or
100 mg/day) in 50 Japanese patients with
T2DM, a significant reduction in HbA1c and
reduced insulin dosage was observed after
24 weeks in the sitagliptin add-on group [7].
There is also an observational study that
investigated the effects of combination
therapy of sitagliptin and insulin in Japanese
patients with T2DM receiving different insulin
regimens [8]. The present study is different from
those studies in the following aspects. The
present study demonstrated a longer-term
(48 weeks) and stable glycemic control by the
add-on therapy with sitagliptin. By comparing
patient groups who were matched with HbA1c
and other factors, the effects of the add-on
therapy with sitagliptin by different insulin
regimens over a longer period of time were
determined. Stable efficacy across patients with
different background factors such as
concomitant drugs, BMI, and CPI was
confirmed.
To date, the influence of sitagliptin on the
insulin dosage had not been fully evaluated in
Japanese patients because sitagliptin is
administered in combination with a fixed dose
of insulin (mainly twice daily premixed
insulin). This study showed that the insulin
dosage was significantly reduced after 48 weeks
of the add-on therapy with sitagliptin. Among
the 42 patients also receiving treatment with
sulfonylureas, the sulfonylurea dosage was
increased in only three patients, while it was
decreased in 10 patients and sulfonylureas were
discontinued in two patients. Moreover, CPI
was significantly higher than baseline after
48 weeks of the add-on therapy with
sitagliptin, indicating that endogenous insulin
secretion was maintained and even improved.
Therefore, the stable hypoglycemic effect
obtained by concomitant use of sitagliptin
attenuated glucotoxicity and maintained
pancreatic b-cell function, leading to lower
insulin dosages and dose reduction of
sulfonylurea therapy. Since concomitant use of
sitagliptin was not associated with an increase
in the insulin dosage over the medium term
(48 weeks), this combination may be beneficial
for glycemic control.
The stratified analysis of the improvement of
HbA1c in relation to age, duration of diabetes,
BMI, CPI, insulin regimen, and oral antidiabetic
drugs did not identify any of these parameters
as being influential on HbA1c. In the authors’
previous 12-week investigation, improvement
of HbA1c was largest in patients treated with
basal insulin and sitagliptin (basal insulin
group). In this study, a decrease in HbA1c was
observed after 48 weeks even in the multiple
injections group, and there was no significant
difference in the changes in HbA1c among the
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three insulin regimens. As far as we know, there
have been no other reports on the comparison
of the HbA1c-lowering effect of the add-on
therapy among three insulin regimens for the
period over 24 weeks.
Moreover, there has been no report on the
differences in the inhibitory effect on the
increase of postprandial blood glucose.
Takahara et al. [9] investigated the influence of
sitagliptin combined with basal insulin on the
diurnal variation of blood glucose by
self-monitoring of blood glucose. They
reported that both HbA1c and the M value (an
index of diurnal variation of blood glucose)
were significantly improved, and that diurnal
variation of blood glucose was improved along
with inhibition of postprandial hyperglycemia.
The possibility was suggested that adding
sitagliptin to twice daily premixed insulin
could improve postprandial blood glucose
[10]. In the twice daily group and basal insulin
group in the current study, postprandial
hyperglycemia had not been satisfactorily
controlled prior to combined therapy, but it
was improved by add-on sitagliptin; also,
HbA1c decreased during the relatively short
period of 12 weeks. However, the authors
consider that further improvement of HbA1c
over time is not likely in these patients, and
other treatment will be needed. With regard to
the influence of CPI on HbA1c, the authors
found that HbA1c was improved without
weight gain after 48 weeks of the add-on
treatment, even in patients with baseline CPI
\0.8 who may have insulin hypo-secretion.
In this study, there was an improvement in
CPI in the twice daily insulin group, but no
change was observed in the multiple injections
group and the basal insulin group. The authors
consider the following possible reasons: almost
all patients in the multiple injections group had
required basal insulin therapy at baseline. Thus,
endogenous insulin secretion capacity may
have been exhausted in those patients, which
caused no improvement in endogenous insulin
after the addition of sitagliptin. In addition, a
difference in the number of patients included in
each group (14 patients in the multiple
injections group vs. 44 patients in the twice
daily group) may have contributed. As shown in
Table 5, the change in CPI was largest in the
basal insulin group, followed by the multiple
injections group. Nevertheless, a significant
increase in CPI was observed only in the twice
daily group. This may be because of the small
number of patients in the multiple injections
group, causing insufficient power to detect a
significant difference.
Dipeptidyl peptidase-4 inhibitors have both
a glucose-dependent insulinotropic effect and a
glucagonostatic effect, which contribute
equally to the glucose-lowering action of these
drugs [11]. Sitagliptin has been reported to
reduce blood glucose in patients with type 1
diabetes treated with insulin [12], and a
glucagonostatic effect of glucagon-like
peptide-1 receptor agonists was also reported
in patients with type 1 diabetes [13]. In patients
with impaired endogenous insulin secretion, it
is probable that the glucagonostatic effect could
be more important than the improvement of
endogenous insulin secretion soon after
initiation of sitagliptin treatment, while a
blood glucose-lowering effect similar to that in
patients with CPI C0.8 was seen after 48 weeks
owing to improvement of insulin secretion over
time as a result of the suppression of
glucotoxicity.
It should be noted that the glucose-lowering
efficacy of DPP-4 inhibitors may be greater in
Asian populations including Japanese [14],
thus, the results of the present study may be
different in Western populations. In terms of
the effects of sitagliptin in Caucasians, a
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large-scale randomized, double-blind,
placebo-controlled, 24-week clinical trial in
which treatment with sitagliptin 100 mg/day
or placebo was administered concurrently with
insulin glargine titration has been conducted
[15]. The present study is similar to this study in
that, the add-on therapy with sitagliptin led to a
decrease in HbA1c, decreased insulin dosage
and reduced hypoglycemia incidence. However,
unlike the present study, the insulin therapy
was limited to insulin glargine. The authors
believe that the present study is beneficial as it
determined the add-on effects of sitagliptin
given over a longer time with different types
of insulin regimens.
CONCLUSIONS
In conclusion, add-on therapy with sitagliptin
maintained stable glycemic control for 48 weeks
without weight gain or problematic adverse
events in patients with poor baseline glycemic
control despite various insulin regimens. The
authors’ finding that endogenous insulin
secretion was increased after 48 weeks
compared with that measured at the initiation
of the add-on therapy suggests that long-term
treatment may be beneficial. However, a
randomized controlled trial is necessary to
confirm these results.
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